← All trials
NCT04893187
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 15, 2021
- Primary completion
- Dec 31, 2022
- Completion date
- Jun 30, 2023
- First posted
- May 19, 2021
- Last posted
- May 19, 2021
- Enrollment
- 76
- Arms / groups
- 6 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Sunshine Lake Pharma Co., Ltd.Lead sponsor
- Guangzhou Medical UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.